Literature DB >> 19906677

RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease.

Fang Fang1, Lih-Fen Lue, Shiqiang Yan, Hongwei Xu, John S Luddy, Doris Chen, Douglas G Walker, David M Stern, Shifang Yan, Ann Marie Schmidt, John X Chen, Shirley ShiDu Yan.   

Abstract

Microglia are critical for amyloid-beta peptide (Abeta)-mediated neuronal perturbation relevant to Alzheimer's disease (AD) pathogenesis. We demonstrate that overexpression of receptor for advanced glycation end products (RAGE) in imbroglio exaggerates neuroinflammation, as evidenced by increased proinflammatory mediator production, Abeta accumulation, impaired learning/memory, and neurotoxicity in an Abeta-rich environment. Transgenic (Tg) mice expressing human mutant APP (mAPP) in neurons and RAGE in microglia displayed enhanced IL-1beta and TNF-alpha production, increased infiltration of microglia and astrocytes, accumulation of Abeta, reduced acetylcholine esterase (AChE) activity, and accelerated deterioration of spatial learning/memory. Notably, introduction of a signal transduction-defective mutant RAGE (DN-RAGE) to microglia attenuates deterioration induced by Abeta. These findings indicate that RAGE signaling in microglia contributes to the pathogenesis of an inflammatory response that ultimately impairs neuronal function and directly affects amyloid accumulation. We conclude that blockade of microglial RAGE may have a beneficial effect on Abeta-mediated neuronal perturbation relevant to AD pathogenesis.-Fang, F., Lue, L.-F., Yan, S., Xu, H., Luddy, J. S., Chen, D., Walker, D. G., Stern, D. M., Yan, S., Schmidt, A. M., Chen, J. X., Yan, S. S. RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19906677      PMCID: PMC3231946          DOI: 10.1096/fj.09-139634

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  81 in total

1.  Inflammation and Alzheimer disease: the good, the bad, and the ugly.

Authors:  S C Weninger; B A Yankner
Journal:  Nat Med       Date:  2001-05       Impact factor: 53.440

2.  Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice.

Authors:  Michael T Heneka; Magdalena Sastre; Lucia Dumitrescu-Ozimek; Anne Hanke; Ilse Dewachter; Cuno Kuiperi; Kerry O'Banion; Thomas Klockgether; Fred Van Leuven; Gary E Landreth
Journal:  Brain       Date:  2005-04-07       Impact factor: 13.501

3.  Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-beta-mediated cortical synaptic dysfunction.

Authors:  Nicola Origlia; Massimo Righi; Simona Capsoni; Antonino Cattaneo; Fang Fang; David M Stern; John Xi Chen; Ann Marie Schmidt; Ottavio Arancio; Shi Du Yan; Luciano Domenici
Journal:  J Neurosci       Date:  2008-03-26       Impact factor: 6.167

4.  p38 kinase is activated in the Alzheimer's disease brain.

Authors:  K Hensley; R A Floyd; N Y Zheng; R Nael; K A Robinson; X Nguyen; Q N Pye; C A Stewart; J Geddes; W R Markesbery; E Patel; G V Johnson; G Bing
Journal:  J Neurochem       Date:  1999-05       Impact factor: 5.372

5.  Transgenic AD model mice, effects of potential anti-AD treatments on inflammation and pathology.

Authors:  Thomas van Groen; Inga Kadish
Journal:  Brain Res Brain Res Rev       Date:  2005-04

6.  Beta-amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor alpha and NMDA receptors.

Authors:  Angela M Floden; Shanshan Li; Colin K Combs
Journal:  J Neurosci       Date:  2005-03-09       Impact factor: 6.167

7.  P38 MAP kinase is activated at early stages in Alzheimer's disease brain.

Authors:  Anyang Sun; Mei Liu; Xuan V Nguyen; Guoying Bing
Journal:  Exp Neurol       Date:  2003-10       Impact factor: 5.330

8.  Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's disease.

Authors:  Miles C Miller; Rosemarie Tavares; Conrad E Johanson; Virginia Hovanesian; John E Donahue; Liliana Gonzalez; Gerald D Silverberg; Edward G Stopa
Journal:  Brain Res       Date:  2008-07-14       Impact factor: 3.252

9.  Beta-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway.

Authors:  Maria Grazia Giovannini; Carla Scali; Costanza Prosperi; Arianna Bellucci; Maria Giuliana Vannucchi; Susanna Rosi; Giancarlo Pepeu; Fiorella Casamenti
Journal:  Neurobiol Dis       Date:  2002-11       Impact factor: 5.996

10.  Interleukin-1 mediates Alzheimer and Lewy body pathologies.

Authors:  W Sue T Griffin; Ling Liu; Yuekui Li; Robert E Mrak; Steven W Barger
Journal:  J Neuroinflammation       Date:  2006-03-16       Impact factor: 8.322

View more
  108 in total

1.  Microglial receptor for advanced glycation end product-dependent signal pathway drives beta-amyloid-induced synaptic depression and long-term depression impairment in entorhinal cortex.

Authors:  Nicola Origlia; Camilla Bonadonna; Alfredo Rosellini; Elena Leznik; Ottavio Arancio; Shirley Shidu Yan; Luciano Domenici
Journal:  J Neurosci       Date:  2010-08-25       Impact factor: 6.167

2.  The inhalation anesthetic isoflurane increases levels of proinflammatory TNF-α, IL-6, and IL-1β.

Authors:  Xu Wu; Yan Lu; Yuanlin Dong; Guohua Zhang; Yiying Zhang; Zhipeng Xu; Deborah J Culley; Gregory Crosby; Edward R Marcantonio; Rudolph E Tanzi; Zhongcong Xie
Journal:  Neurobiol Aging       Date:  2010-12-28       Impact factor: 4.673

3.  β-Asarone Mitigates Amyloidosis and Downregulates RAGE in a Transgenic Mouse Model of Alzheimer's Disease.

Authors:  Cong Yang; Xiaoguang Li; Yousheng Mo; Sijun Liu; Luguang Zhao; Xiaohui Ma; Zhigang Fang; Junli Chen; Yunbo Chen; Xuhua Yu; Shuhuan Fang; Yongbin Zhang; Shaoxiang Xian; Qi Wang
Journal:  Cell Mol Neurobiol       Date:  2015-08-14       Impact factor: 5.046

4.  Hypertension induces brain β-amyloid accumulation, cognitive impairment, and memory deterioration through activation of receptor for advanced glycation end products in brain vasculature.

Authors:  Daniela Carnevale; Giada Mascio; Ivana D'Andrea; Valentina Fardella; Robert D Bell; Igor Branchi; Fabio Pallante; Berislav Zlokovic; Shirley Shidu Yan; Giuseppe Lembo
Journal:  Hypertension       Date:  2012-05-21       Impact factor: 10.190

Review 5.  The neglected co-star in the dementia drama: the putative roles of astrocytes in the pathogeneses of major neurocognitive disorders.

Authors:  W K Jo; A C K Law; S K Chung
Journal:  Mol Psychiatry       Date:  2014-01-07       Impact factor: 15.992

Review 6.  The role of neuroimmune signaling in alcoholism.

Authors:  Fulton T Crews; Colleen J Lawrimore; T Jordan Walter; Leon G Coleman
Journal:  Neuropharmacology       Date:  2017-02-01       Impact factor: 5.250

7.  Multi-faced neuroprotective effects of Ginsenoside Rg1 in an Alzheimer mouse model.

Authors:  Fang Fang; Xiaochun Chen; Tianwen Huang; Lih-Fen Lue; John S Luddy; Shirley Shidu Yan
Journal:  Biochim Biophys Acta       Date:  2011-10-12

8.  Genetic ablation of receptor for advanced glycation end products promotes functional recovery in mouse model of spinal cord injury.

Authors:  Ji-Dong Guo; Li Li; Ya-Min Shi; Hua-Dong Wang; Yan-Li Yuan; Xiu-Xiu Shi; Shu-Xun Hou
Journal:  Mol Cell Biochem       Date:  2014-02-14       Impact factor: 3.396

9.  Mrp14 deficiency ameliorates amyloid β burden by increasing microglial phagocytosis and modulation of amyloid precursor protein processing.

Authors:  Markus P Kummer; Thomas Vogl; Daisy Axt; Angelika Griep; Ana Vieira-Saecker; Frank Jessen; Ellen Gelpi; Johannes Roth; Michael T Heneka
Journal:  J Neurosci       Date:  2012-12-05       Impact factor: 6.167

Review 10.  Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer's disease Neurons.

Authors:  Ravi Rajmohan; P Hemachandra Reddy
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.